Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy

Fig. 6

Combined CN133 with PD-1 did not improve the anti-tumor efficacy on the FVB mice bearing murine RM1 bone metastatic PCa tumors. A Timeline of mouse models of bone metastasis PCa with PD-1 or PD-1 plus CN133 treatment schedules (left) and BLI showing the luciferase intensity of bone tumors at day 25 (right). B, C Flow cytometric analyses examined positive percentages of MDSCs (B) and Arg-1 and iNOS (C) in the bone marrow PCa at day 25. D Activity cytokines of MDSCs were tested in the RM1 cell of bone metastatic PCa tumor by RT-qPCR

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us